Trial Profile
A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms TOPICAL
- 06 Sep 2019 Results assessing the clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy, published in the European Journal of Cancer
- 09 Sep 2015 Results assessing values of veriStrat classifier presented at the 16th World Conference on Lung Cancer.
- 15 Oct 2012 Primary endpoint 'Overall-survival-duration' has not been met.